Pasithea Therapeutics (KTTA) Stock Price, News & Analysis

Company Overview

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Key Stats

• Today's Range: $3.19 to $3.42
• 50-Day Range: $3.30 to $6.09
• 52-Week Range: $3.19 to $17.40
• Volume: 23,741 shs
• Average Volume: 286,469 shs
• Market Capitalization: $3.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Pasithea Therapeutics Stock Analysis - MarketRank™

Pasithea Therapeutics scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Pasithea Therapeutics.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Pasithea Therapeutics has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.45% of the float of Pasithea Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Pasithea Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pasithea Therapeutics has recently decreased by 49.12%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pasithea Therapeutics does not currently pay a dividend.

Dividend Growth

Pasithea Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.45% of the float of Pasithea Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Pasithea Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pasithea Therapeutics has recently decreased by 49.12%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.18

News Sentiment

Pasithea Therapeutics has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Pasithea Therapeutics this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for KTTA on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pasithea Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.30% of the stock of Pasithea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 23.92% of the stock of Pasithea Therapeutics is held by institutions.

KTTA Stock Analysis - Frequently Asked Questions

How have KTTA shares performed this year?

Pasithea Therapeutics' stock was trading at $7.40 at the beginning of 2024. Since then, KTTA stock has decreased by 54.3% and is now trading at $3.38.
View the best growth stocks for 2024 here.

When did Pasithea Therapeutics' stock split?

Shares of Pasithea Therapeutics reverse split on the morning of Tuesday, January 2nd 2024. The 1-20 reverse split was announced on Tuesday, January 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Pasithea Therapeutics IPO?

Pasithea Therapeutics (KTTA) raised $17 million in an initial public offering on Wednesday, September 15th 2021. The company issued 2,898,551 shares at a price of $5.00-$7.00 per share.

How do I buy shares of Pasithea Therapeutics?

Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Pasithea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pasithea Therapeutics investors own include Biofrontera (BFRI), Meta Platforms (META), Plug Power (PLUG), QuantumScape (QS), Airbnb (ABNB), Advanced Micro Devices (AMD) and Ginkgo Bioworks (DNA).

Company Calendar

• Today: 11/16/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KTTA
• CUSIP: N/A
• CIK: 1841330
• Web: www.pasithea.com
• Phone: 702-514-4174
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-15,960,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -79.51%
• Return on Assets: -71.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.20
• Quick Ratio: 6.19

Sales & Book Value

• Annual Sales: $20,000.00
• Price / Sales: 176.61
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $22.46 per share
• Price / Book: 0.15

Miscellaneous

• Outstanding Shares: 1,045,000
• Free Float: 875,000
• Market Cap: $3.53 million
• Optionable: Not Optionable
• Beta: 0.82